MedTrace Logo

Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound

NCT00655512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-06-11

No results posted yet for this study

Summary

to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream

Conditions

  • Healthy

Interventions

DRUG

pimecrolimus 1% cream

twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

DRUG

hydrocortisonacetat 1% cream

twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

DRUG

betamethasonvalerat 0,1% cream

twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

DRUG

clobetasol-17-propionat 0,05% cream

twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

DRUG

Placebo

twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Roland Aschoff, MD · Department of Dermatology, Medical Faculty, Technical University Dresden, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-06-30
Completion
2008-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655512 on ClinicalTrials.gov